RxDoctor Payments Data

Avelino Pinon, MD

Urology · Miami, FLNPI 1164495362

Payments from drug & device makers

$6,288in general payments, 2019–2025

Across 181 payments — averaging $34.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • KARL Storz Endoscopy-america$1K
  • Medtronic$1K
  • Johnson & Johnson$834
  • Astellas Pharma US Inc$590
  • Procept Biorobotics Corporation$554
  • Boston Scientific$374
  • plus $2K from 24 others

What the payments were for

  • Travel & lodging$98216%
  • Food & beverage$5,14982%
  • Education$1572%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,288 in reported general payments places this provider in the 60th percentile of 935 urology providers in Florida.

See all urology providers in Florida

Medicare billing

Part B allowed, 2024
$119,318
Medicare patients
349
Services billed
3,229

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrelstarTriptorelin Pamoate195$346,773
Lupron DepotLeuprolide Acetate37$164,216
MyrbetriqMirabegron172$139,224
Mitomycin34$35,654
GemtesaVibegron40$35,534
Tamsulosin Hcl1,513$16,599
EligardLeuprolide Acetate14$14,020
Tadalafil28$5,657
Alfuzosin Hcl ErAlfuzosin Hcl200$5,465
Finasteride613$5,288
Dutasteride189$4,697
Testosterone Cypionate117$3,720
Sildenafil Citrate494$3,718
Oxybutynin Chloride ErOxybutynin Chloride163$2,970
Estradiol46$2,794

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Verity Pharmaceuticals Inc.Trelstar$88$346,773195 claims
Astellas Pharma US IncMyrbetriq$590$139,224172 claims
Sumitomo Pharma America, Inc.Gemtesa$129$35,53440 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 935 urology providers in Florida.

Other urology in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →